Early Diagnosis with 11-Gene Panel Screening for Non Small Cell Lung Cancer

Non-small cell lung cancer: early stages.

More than 170 000 new cases and 150 000 deaths have occurred in 2003 in US owing to lung cancer, which is the leading cancer death reason for men in US. Non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancers [1, 2]. Despite the progress in imaging and diagnostic procedures, non-small cell lung cancer (NSCLC) usually presents as advanced (locally or more frequently dissemi...

Clinicopathological Features of Patients with Non-small-cell Lung Cancer in West of Iran

Background: Lung cancer is the most common cause of cancer death worldwide with an annual mortality rate of more than 1.3 million worldwide. We aimed to analyze the clinicopathological features of patients with non-small-cell lung cancer (NSCLC) in west of Iran. Methods: 64 patients with NSCLC who referred to our clinic were analyzed. Sex, age, histopathology, location of the tumor, treatment,...

NCCN Non-Small Cell Lung Cancer Panel Members

Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer-related mortality in the developed world. Non-small cell lung cancer (NSCLC) represents 85% of cases of lung cancer, and patients have a poor 5-year survival rate. Approximately one third of NSCLC patients present with early-stage disease that is amenable to potentially curative resection and multimodality therapy. Several randomized trials now have co...

Stereotactic radiotherapy for early stage non-small cell lung cancer

Stereotactic body radiotherapy (SBRT) represents a consolidated treatment option for patients with medically inoperable early stage non-small cell lung cancer (NSCLC). The clinical evidence accumulated in the past decade supports its use as an alternative to surgery with comparable survival outcomes. Due to its limited toxicity, SBRT is also applicable to elderly patients with very poor baselin...